Loading clinical trials...
Loading clinical trials...
The October 2022 Transparency Commission considers that VYEPTI (eptinezumab) is a treatment option for patients suffering from severe migraine with at least 8 migraine days per month, who have failed ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
NCT07348783 · Cluster Headache - Episodic and Chronic, Migraine Headache, and more
NCT06229834 · Episodic Migraine
NCT06603558 · Chronic Migraine, Episodic Migraine, and more
NCT05987592 · Migraine
NCT07103694 · Episodic Migraine, Chronic Migraine, and more
CHU de Nîmes
Nîmes
CH de Saint Denis
Saint-Denis
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions